Nevirapine | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

Nevirapine
Health Canada Patents

EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

Contact Supplier

SPI Pharma has been solving formulation challenges using superior functional materials.

Contact Supplier

Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

Contact Supplier

Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

Contact Supplier

FAMAR CDMO- From early development to commercial manufacturing.

Contact Supplier

Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

Contact Supplier

Nevirapine

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

30 API Suppliers, 18 USDMF, 11 CEP/COS, 1 JDMF, 11 EU WC, 9 NDC API, 9 Listed Suppliers, $ API Reference Price

30 API Suppliers
18 USDMF
11 CEP/COS
1 JDMF
11 EU WC
9 NDC API
9 Listed Suppliers
$ API Reference Price

INTERMEDIATES

11 Intermediate Suppliers

11 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

130 FDF Dossiers, 60 FDA Orange Book, 26 Europe, 4 Canada, 3 Australia, 25 South Africa, 12 Listed Dossiers

130 FDF Dossiers
60 FDA Orange Book
26 Europe
4 Canada
3 Australia
25 South Africa
12 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET, EXTENDED RELEASE;ORAL - 100MG, TABLET, EXTENDED RELEASE;ORAL - 400MG, TABLET;ORAL - 150MG;200MG;300MG, TABLET;ORAL - 200MG, SUSPENSION;ORAL - 50MG/5ML

TABLET, EXTENDED RELEASE;ORAL - 100MG
TABLET, EXTENDED RELEASE;ORAL - 400MG
TABLET;ORAL - 150MG;200MG;300MG
TABLET;ORAL - 200MG
SUSPENSION;ORAL - 50MG/5ML

RELATED EXCIPIENT COMPANIES

1 Minakem, 5 SPI Pharma, 1 DKSH, 5 Faran Shimi Pharmaceutical, 6 Boai NKY Pharmaceuticals Ltd, 1 Chynops Pharma, 6 Gangwal Healthcare, 1 Nanjing Well Pharmaceutical, 1 Pramukh Pharmachem, 1 ACG Worldwide, 1 Actylis, 1 Aeon Procare, 2 Alcedo Pharmachem, 9 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 11 BASF, 10 Corel Pharma Chem, 7 DFE Pharma, 7 Gangwal Chemicals, 1 Huzhou Sunflower Pharmaceutical, 5 Ideal Cures Pvt Ltd, 4 Ingredion Pharma Solutions, 35 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 13 Microlex e.U, 1 NEWEDGE Overseas, 3 Novo Excipients, 4 Pharmatrans-Sanaq, 5 Pluviaendo, 5 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 16 Roquette, 7 Seppic, 6 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 12 Sigachi Industries, 2 The Dow Chemical Company, 1 Ulanqab Kema New Material, 4 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

73 Fillers, Diluents & Binders, 42 Coating Systems & Additives, 30 Disintegrants & Superdisintegrants, 26 Direct Compression, 24 Controlled & Modified Release, 22 Granulation, 21 Lubricants & Glidants, 15 Thickeners and Stabilizers, 12 Co-Processed Excipients, 10 Film Formers & Plasticizers, 10 Solubilizers, 8 Chewable & Orodispersible Aids, 8 Taste Masking, 5 Empty Capsules, 5 API Stability Enhancers, 4 Vegetarian Capsules, 4 Emulsifying Agents, 3 Rheology Modifiers, 3 Parenteral, 2 Coloring Agents

73 Fillers, Diluents & Binders
42 Coating Systems & Additives
30 Disintegrants & Superdisintegrants
26 Direct Compression
24 Controlled & Modified Release
22 Granulation
21 Lubricants & Glidants
15 Thickeners and Stabilizers
12 Co-Processed Excipients
10 Film Formers & Plasticizers
10 Solubilizers
8 Chewable & Orodispersible Aids
8 Taste Masking
5 Empty Capsules
5 API Stability Enhancers
4 Vegetarian Capsules
4 Emulsifying Agents
3 Rheology Modifiers
3 Parenteral
2 Coloring Agents

DIGITAL CONTENT

11 NEWS #PharmaBuzz

11 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions, 26 Finished Drug Prices

2 US Medicaid Prescriptions
26 Finished Drug Prices

MARKET PLACE

7 APIs, 6 FDF Dossiers

7 APIs
6 FDF Dossiers

PATENTS & EXCLUSIVITIES

1 US Patents, 2 Health Canada Patents

1 US Patents
2 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 EDQM, 5 USP, 4 Others

3 EDQM
5 USP
4 Others

ANALYTICAL

1 BioAnalytical Methods

1 BioAnalytical Methods

$ API Ref.Price (USD/KG) : 162 Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

2 All

01 2Boehringer Ingelheim (Canada) Ltd.

filter Patent Reset all filters

2 All

01 12030056

02 12687491

filter Product Reset all filters

2 All

01 2Nevirapine

filter Dosage Reset all filters

2 All

01 2Tablet

filter Exp Date Reset all filters

2 All

01 12010-11-15

02 12028-06-04

Product Main Page

01

Boehringer Ingelheim (Canada) Ltd.

Nevirapine

BioAsia

Not Confirmed

Boehringer Ingelheim (Canada) Ltd.

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2010-11-15

Date Granted : 1995-10-17

Brand Name : VIRAMUNE

Patent Number : 2030056

Filing Date : 1990-11-15

Strength per Unit : 200mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2010-11-15

Date Granted : 1995-10-17

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

Boehringer Ingelheim (Canada) Ltd.

Nevirapine

BioAsia

Not Confirmed

Boehringer Ingelheim (Canada) Ltd.

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2028-06-04

Date Granted : 2011-09-20

Brand Name : VIRAMUNE XR

Patent Number : 2687491

Filing Date : 2008-06-04

Strength per Unit : 400 mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2028-06-04

Date Granted : 2011-09-20

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
ASK US!